Compare PED & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | ENTX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0M | 147.4M |
| IPO Year | 2012 | 2015 |
| Metric | PED | ENTX |
|---|---|---|
| Price | $14.79 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 19.7K | ★ 671.8K |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $45,751,000.00 | $42,000.00 |
| Revenue This Year | $212.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.68 |
| Revenue Growth | ★ 15.67 | N/A |
| 52 Week Low | $8.64 | $0.91 |
| 52 Week High | $133.98 | $4.20 |
| Indicator | PED | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 53.62 |
| Support Level | $14.12 | $2.71 |
| Resistance Level | $16.70 | $3.08 |
| Average True Range (ATR) | 0.61 | 0.20 |
| MACD | 0.19 | 0.05 |
| Stochastic Oscillator | 92.35 | 55.76 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.